Isis Pharmaceuticals Reports Interim Results from ISIS-SMN Rx Multiple Dose Study in Children with Spinal Muscular Atrophy

[PR Newswire] – CARLSBAD, Calif., Feb. 21, 2014 /PRNewswire/ — Isis Pharmaceuticals, Inc. (ISIS) today announced top-line results from an ongoing open-label, multiple-dose study of ISIS-SMNRx in children with spinal muscular atrophy (SMA). In this study more

View todays social media effects on ISIS

View the latest stocks trending across Twitter. Click to view dashboard

See who Isis is hiring next, click here to view